To elucidate the impact of infused CD34⁺ cell doses on transplant outcome, we retrospectively analyzed 851 adult patients who received peripheral blood stem cell transplantation (PBSCT) from human leukocyte antigen (HLA)-matched related donors. The patients were divided into high- and low-CD34 groups at the cutoff value of 4.5 × 10⁶/kg. Overall, the high CD34 group showed early neutrophil and platelet recovery. Stratification of disease risks demonstrated that among the patients with low-risk diseases, the high-CD34 group showed better disease-free survival (DFS) (64.9% vs. 55.5%, P = 0.0415) than did the low-CD34 group, without any increase in graft-versus-host disease (GVHD). Meanwhile, a higher CD34⁺ cell dose had no impacts on the outcomes of patients with high-risk diseases. Multivariate analyses for the patients with low-risk diseases revealed that a high CD34⁺ cell dose (hazard ratio [HR] 0.72, P = 0.048) and development of grade III-to-IV acute GVHD (HR 1.64, P = 0.018) were significantly associated with DFS. An excessive dose of CD34⁺ cells (>8.0 × 10⁶/kg) led to an increase in acute GVHD. By stratification of disease risk, a CD34⁺ cell dose between 4.5 and 8.0 × 10⁶/kg can be suggested for patients with low-risk diseases who undergo PBSCT from HLA-matched related donors.

为了阐明注入的 CD34 ⁺细胞剂量对移植结果的影响，我们回顾性分析了 851 名接受人类白细胞抗原 (HLA) 匹配的相关供体的外周血干细胞移植 (PBSCT) 的成年患者。^{以4.5×10 6} /kg的临界值将患者分为高CD34组和低CD34组。总体而言，高 CD34 组显示早期中性粒细胞和血小板恢复。疾病风险分层表明，在低风险疾病患者中，高 CD34 组的无病生存期 (DFS)（64.9% vs. 55.5%，P  = 0.0415）优于低 CD34 组，无移植物抗宿主病 (GVHD) 的任何增加。同时，更高的 CD34 ⁺细胞剂量对高危疾病患者的预后没有影响。对低风险疾病患者的多变量分析显示，高 CD34 ⁺细胞剂量（风险比 [HR] 0.72，P  = 0.048）和发展为 III 至 IV 级急性 GVHD（HR 1.64，P  = 0.018）与 DFS 显着相关。过量剂量的 CD34 ⁺细胞 (>8.0 × 10 ⁶ /kg) 导致急性 GVHD 增加。通过疾病风险的分层，对于从 HLA 匹配的相关供体接受 PBSCT 的低风险疾病患者，可以建议CD34 ⁺细胞剂量在 4.5 和 8.0 × 10 ^{6 /kg 之间。}